Glucagon and GLP-1 receptor co-agonist
Survodutide 3.6 mg subcutaneous once weekly
SURV_SC_3p6MG_QW
Related
- All doses pooled: Survodutide injection
- Survodutide 0.3 mg subcutaneous once weekly
- Survodutide 0.9 mg subcutaneous once weekly
- Survodutide 1.8 mg subcutaneous once weekly
- Survodutide 2.7 mg subcutaneous once weekly
- Survodutide 1.2 mg injection
- Survodutide 1.8 mg injection
- Survodutide 6.0 mg subcutaneous once weekly
- Survodutide 0.6 mg subcutaneous once weekly
- Survodutide 2.4 mg subcutaneous once weekly
- Survodutide 4.8 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -10.02 (-14.69 to -4.61) | 0.51 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 9.31 (1.75 to 34.04) | 0.70 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 10.74 (2.17 to 34.10) | 0.63 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 9.41 (2.33 to 34.98) | 0.63 |